Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8N1G0

UPID:
ZN687_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8N1G0; D3DV17; Q68DQ8; Q9H937; Q9P2A7

BACKGROUND:
The Zinc finger protein 687, with its potential involvement in transcriptional regulation, represents a key player in gene expression processes. This protein, identified by the unique identifier Q8N1G0, is believed to interact with DNA through its zinc finger domains, influencing cellular pathways and functions.

THERAPEUTIC SIGNIFICANCE:
Linked to Paget disease of bone 6, Zinc finger protein 687's role in bone metabolism and remodeling is of significant interest. The disease's connection to variants affecting this gene highlights the protein's potential as a target for therapeutic intervention, offering hope for treatments addressing bone disorders and their complications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.